Lupus Science & Medicine

Papers
(The TQCC of Lupus Science & Medicine is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)
ArticleCitations
SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort64
Novel multiclass classification machine learning approach for the early-stage classification of systemic autoimmune rheumatic diseases51
Towards a minimal core dataset for systemic lupus erythematosus studies50
B lymphocytes in treatment-naive paediatric patients with lupus are epigenetically distinct from healthy children49
Evaluation and randomised controlled trial of home urinalysis testing in patients with SLE at elevated risk for developing lupus nephritis: a study protocol46
Differences in reproductive health discussions in an urban Hispanic population with SLE: lessons from the field43
Genetic load in incomplete lupus erythematosus41
High-dimensional analysis of T-cell profiling variations following belimumab treatment in systemic lupus erythematosus38
Intermittent and Persistent Type 2 lupus: patient perspectives on two distinct patterns of Type 2 SLE symptoms38
Autoantibody-based subgroups and longitudinal seroconversion in juvenile-onset systemic lupus erythematosus34
Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE33
Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease29
A better self-efficacy is predictive of better health-related quality of life (HRQoL) in patients with systemic lupus erythematosus: data from the Almenara Lupus Cohort28
Langerhans cells infiltration in lymph nodes of patients with systemic lupus erythematosus28
Therapy with direct oral anticoagulants for secondary prevention of thromboembolic events in the antiphospholipid syndrome: a systematic review and meta-analysis of randomised trials25
B cell polygenic risk scores associate with anti-dsDNA antibodies and nephritis in systemic lupus erythematosus25
VPS13C and STING expression in neuropsychiatric systemic lupus erythematosus: unveiling an unbreached territory24
Disease activity trajectories in paediatric lupus and associations with socioeconomic factors and patient-reported pain24
Mesenchymal stem cells improve ovarian function by suppressing fibrosis through CTGF/FAK signalling in systemic lupus erythematosus24
Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial22
Generation of evidence supporting the content validity of SF-36, FACIT-F, and LupusQoL, and novel patient-reported symptom items for use in patients with systemic lupus erythematosus (SLE) and SLE wit22
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine21
Renal response status to predict long-term renal survival in patients with lupus nephritis: results from the Toronto Lupus Cohort21
Novel immunoprofiling method for diagnosing SLE and evaluating therapeutic response21
Anti-CD20 alone as maintenance immunosuppressive therapy in severe lupus nephritis: a promising experience that needs to be evaluated20
Add-on sirolimus for the treatment of mild or moderate systemic lupus erythematosus via T lymphocyte subsets balance20
Impaired regulatory function of granzyme B-producing B cells against T cell inflammatory responses in lupus mice20
Clarifying misbeliefs about hydroxychloroquine (HCQ): developing the HCQ benefits versus harm decision aid (HCQ-SAFE) per low health literacy standards20
Racial differences in clinical trial perceptions among a large, predominantly Black cohort of people with systemic lupus erythematosus in the Southeastern USA20
Prediction model for renal outcomes in Latin American Mestizo patients with pure proliferative lupus nephritis19
Frequency-dependent and temporal variability of low-frequency fluctuations in patients with primary Sjögren’s syndrome19
Cortical changes in women with systemic lupus erythematosus with mild cognitive impairment: a voxel-based morphometry and surface-based morphometry study19
Large overlap in neutrophil transcriptome between lupus and COVID-19 with limited lupus-specific gene expression18
Investigation of the performance of validated cardiovascular risk scores in a global (UK/US) cohort of young people with childhood-onset systemic lupus erythematosus17
Prevalence and determinants of vertebral fractures in a SLE cohort17
Sirolimus versus tacrolimus for systemic lupus erythematosus treatment: results from a real-world CSTAR cohort study16
Long-term efficacy and safety of the Lupus-Cruces Nephritis protocol: a propensity score study of the Lupus-Cruces and Lupus-Bordeaux cohorts16
To treat or not to treat with immunosuppressive therapy: psychiatric disorders in patients with systemic lupus erythematosus16
Clinical features of Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuritis associated with SLE16
Comorbidity clusters and their relationship with severity and outcomes of index diseases, in a large multicentre systemic lupus erythematosus cohort16
Comorbid psoriasis in systemic lupus erythematosus: a cohort study from a tertiary referral centre and the National Patient Register in Sweden16
Neutrophil gelatinase-associated lipocalin (NGAL) in lupus nephritis and beyond15
Cardiovascular risk management in antiphospholipid syndrome: trends over time and comparison with rheumatoid arthritis and diabetes mellitus15
Clinical and immunological differences between primary and autoimmune-associated neuromyelitis optica spectrum disorders: a retrospective study15
Genotype-guided new approach for dose optimisation of hydroxychloroquine administration in Chinese patients with SLE15
Dyspigmentation and scarring in cutaneous lupus erythematosus15
Canadian patient experiences of lupus nephritis: a qualitative analysis15
Item-specific factors associated with damage accrual in systemic lupus erythematosus: insights from a multiethnic, multinational Latin American cohort15
Autoantibodies associated with systemic sclerosis in three autoimmune diseases imprinted by type I interferon gene dysregulation: a comparison across SLE, primary Sjögren’s syndrome and systemic scler15
Patient and healthcare team recommended medication adherence strategies for hydroxychloroquine: results of a qualitative study informing intervention development15
Altered hippocampal connectivity dynamics predicts memory performance in neuropsychiatric lupus: a resting-state fMRI study using cross-recurrence quantification analysis14
Autoimmune encephalitis associated with anti-LGI1 antibody: a potential cause of neuropsychiatric systemic lupus erythematosus14
Lupus nephritis randomised controlled trials: evidence gaps and under-represented groups14
Metabolic profiles of cutaneous lupus have abnormalities in the nicotinamide adenine dinucleotide pathway14
Rare and common single nucleotide variants in childhood-onset systemic lupus erythematosus14
Systematic review of the reporting of extrarenal manifestations in observational studies of Saudi patients with systemic lupus erythematosus13
Glucocorticoid tapering early in the course of juvenile SLE: association with lupus low disease activity state and outcomes13
Cardiovascular risk factors and complications in patients with systemic lupus erythematosus with and without nephritis: a systematic review and meta-analysis13
Evaluation of the Montreal Cognitive Assessment as a screening tool for cognitive dysfunction in SLE13
Meeting report: patient and caregiver recommendations for a mobile health application for paediatric systemic lupus erythematosus13
Prevalence and predictive factors associated with sustained remission in SLE: a systematic review13
Treatment trends of systemic lupus erythematosus from 2007 to 2023 in the USA13
Potential causal effect of SLE on osteoporosis, and the mediation effect: a Mendelian randomisation study12
Evaluation of the effects of pre-exposure treatment with hydroxychloroquine on the risk of COVID-19 infection and on the efficacy of anti-COVID-19 vaccination during lupus or Gougerot-Sjögren’s diseas12
Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): prespecified analysis of the phase III ustekinumab trial in patients with SLE12
Unmet needs and challenges in the diagnosis and management of antiphospholipid syndrome: a qualitative stakeholder study within the ReCONNET framework12
Unravelling the TCRβ repertoire: a key to unlocking the immunopathogenesis and precision medicine in SLE12
Anti-ribosomal-P protein antibodies and systemic lupus erythematosus (SLE): in a cross-sectional study of Danish adult patients with SLE, no significant association is found between anti-ribosomal-P a12
Improving patient pathways for systemic lupus erythematosus: a multistakeholder pathway optimisation study12
Discrepant anti-dsDNA testing between EliA and Crithidia in ANA negative samples: just a false positive?12
Lupus spectrum ambiguity has long-term negative implications for patients12
Genetic relationships between systemic lupus erythematosus and a positive antinuclear antibody test in the absence of autoimmune disease11
Comparison of short interval and low dose (SILD) with high dose of cyclophosphamide in the susceptibility to infection in SLE: a multicentrereal-world study11
Visceral fat, cardiovascular risk factors and quality of life in lupus activity categorised via complement C311
Enhancing lupus outcomes by means of biology beyond overt clinical features, exemplified in an in-depth investigation of the effects of circadian rhythm disruption11
Levels of physical activity in a large international cohort of patients with systemic lupus erythematosus11
HNF-1β alleviates podocyte injury in lupus nephritis by maintaining endoplasmic reticulum homeostasis11
Development and psychometric evaluation of a physician global assessment for type 2 systemic lupus erythematosus symptoms10
Vitamin D level in patients with systemic lupus erythematosus: its relationship to disease course and bone mineral density10
Elevated serum neurofilament light chain levels in patients with neuropsychiatric systemic lupus erythematosus: a cross-sectional study10
Nailfold capillary scleroderma pattern may be associated with disease damage in childhood-onset systemic lupus erythematosus: important lessons from longitudinal follow-up10
Changes in the incidence and prevalence of systemic lupus erythematosus between 1990 and 2020: an observational study using the Clinical Practice Research Datalink (CPRD)10
Positive psychosocial factors may protect against perceived stress in people with systemic lupus erythematosus with and without trauma history10
Immune complex–driven neutrophil activation and BAFF release: a link to B cell responses in SLE10
Successful autologous CD19 CAR T cell therapy following severe lupus flare during immunosuppressive washout in refractory lupus nephritis10
Risks of mortality and severe coronavirus disease 19 (COVID-19) outcomes in patients with or without systemic lupus erythematosus10
Adverse pregnancy outcomes in women with systemic lupus erythematosus: can we improve predictions with machine learning?9
Proteomics uncovers ICAM2 (CD102) as a novel serum biomarker of proliferative lupus nephritis9
Predictors of treatment response in a lupus nephritis population: lessons from the Aspreva Lupus Management Study (ALMS) trial9
Prediction of mortality risk in critically ill patients with systemic lupus erythematosus: a machine learning approach using the MIMIC-IV database9
Impact of antiphospholipid antibodies on heart valve involvements in systemic lupus erythematosus: based on CSTAR cohort9
Proteins upregulated in thrombotic antiphospholipid syndrome linked to platelet function in contrast with non-antiphospholipid-related thrombosis: insights from two systematic reviews9
Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study9
Validation of eight endotypes of lupus based on whole-blood RNA profiles9
Curcumin attenuates lupus nephritis by inhibiting neutrophil migration via PI3K/AKT/NF-κB signalling pathway9
Evaluation of RNase therapy in systemic lupus erythematosus: a randomised phase 2a clinical trial of RSLV-1329
Factors influencing therapeutic efficacy of denosumab against osteoporosis in systemic lupus erythematosus9
Medium-term impact of the SARS-CoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosus9
Mer-tyrosine kinase: a novel susceptibility gene for SLE related end-stage renal disease9
Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinica9
Higher mortality risk from gynaecological neoplasms and non-Hodgkin’s lymphoma in patients with systemic lupus erythematosus: an observational study from the Spanish National Registry9
Topological structural characteristics in patients with systemic lupus erythematosus with and without neuropsychiatric symptoms9
Pharmacokinetics, effectiveness, tolerability and effect on quality of life of open-label tofacitinib for the treatment of moderately active mucocutaneous manifestations of SLE: results of a 76-week p9
Disease-modifying therapies in systemic lupus erythematosus for extrarenal manifestations8
Relationship between retinal microvascular impairment and subclinical atherosclerosis in SLE8
Clinical outcome in patients with suspected inflammatory neuropsychiatric lupus treated with immunosuppression: an observational cohort study8
Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial8
Association of COVID-19 pandemic-related concern and health routine changes with functioning among individuals with systemic lupus erythematosus8
Assessing the validity of QRISK3 in predicting cardiovascular events in systemic lupus erythematosus8
Dietary Intervention for Systemic Lupus Erythematosus patients based on HLA-DQ2 and DQ8 genotyping (DISH): a protocol for a randomised controlled study8
Identification and functional characterisation of a novel DNASE1L3 variant (c.572A>G, p.Asn191Ser) in three Emirati families with systemic lupus erythematosus and hypocomplementaemic urticarial vas8
0.19167113304138